MYND - MYnd Analytics, Inc.

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
1.1600
-0.2200 (-15.94%)
At close: 4:00PM EDT
Stock chart is not supported by your current browser
Previous Close1.3800
Open1.4000
Bid0.0000 x 1100
Ask0.0000 x 1200
Day's Range1.1500 - 1.4500
52 Week Range0.6200 - 9.8000
Volume481,919
Avg. Volume168,612
Market Cap2.456M
Beta (3Y Monthly)N/A
PE Ratio (TTM)N/A
EPS (TTM)N/A
Earnings DateAug 13, 2018
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est4.75
Trade prices are not sourced from all markets
  • GlobeNewswire

    Telemynd Provides Update Following Spinoff Transaction from Emmaus Life Sciences, Formerly MYnd Analytics

    Telemynd, Inc., a predictive analytics company aimed at improving the delivery of mental health services through the combination of telemedicine and data analytics, today provide a business update following its spinoff from Emmaus Life Sciences, Inc.  (“Emmaus”) (Nasdaq:EMMA), formerly MYnd Analytics, Inc. In connection with the merger between MYnd Analytics, Inc. and Emmaus Life Sciences, Inc., MYnd Analytics contributed its business, assets and liabilities to Telemynd, Inc., which was spun off by means of a pro rata dividend of one share of Telemynd’s common stock for each share of MYnd common stock held at the end of trading on July 16, 2019.  The new shares are expected to begin trading on a standalone basis, at which time further updates will be provided.  In the meantime, additional information is available on the Company’s website and in the Company’s filings with the Securities and Exchange Commission.

  • PR Newswire

    Emmaus Life Sciences Completes Merger

    -- Emmaus Shares Expected to Begin Trading Tomorrow on Nasdaq Under Ticker Symbol "EMMA" -- TORRANCE Calif. , July 17, 2019 /PRNewswire/ --  Emmaus Life Sciences, Inc., a leader in sickle cell ...

  • GlobeNewswire

    MYnd Analytics and Emmaus Life Sciences Stockholders Approve Merger and Spin-off Transactions

    Subject to the satisfaction of the other conditions to the closing of the merger, MYnd will change its name to “Emmaus Life Sciences, Inc.” Emmaus stockholders and other equity holders will receive in the merger shares of common stock of MYnd equal to 94.1% of the fully diluted shares with MYnd stockholders retaining 5.9% of the fully diluted shares. In connection with and prior to the closing of the merger, if all closing conditions are satisfied, MYnd will contribute its current business, assets and liabilities to Telymynd, Inc., its wholly owned subsidiary, and spin off Telemynd by means of a pro rata dividend of one share of Telemynd’s common stock for each share of MYnd common stock held at the end of trading on July 16, 2019.

  • GlobeNewswire

    MYnd Analytics and Emmaus Life Sciences Report Progress on Merger and Spin-off Transaction

    MYnd Analytics, Inc. (MYND) , a predictive analytics company aimed at improving the delivery of mental health services through the combination of telemedicine and data analytics, and Emmaus Life Sciences, Inc. (“Emmaus”), a leader in sickle cell disease treatment, today provided an update on the planned merger and spin-off transaction announced on January 7, 2019. The respective special stockholder meetings will be held today, July 9, 2019, to consider approval of the proposed merger and spin-off transaction.  Subject to approval by holders of record of the companies at the respective special stockholder meetings, MYnd will issue a number of shares of common stock to the current Emmaus shareholders, which will result in MYnd shareholders retaining 5.9% of the fully diluted shares of the 'New Emmaus' post-closing and a pro rata distribution of one share of Telemynd’s common stock for each share of MYnd common stock held at the end of trading on July 16, 2019.  The companies have set a new Spin-Off Record Date of July 15, 2019 in order to comply with certain NASDAQ and DTC requirements.

  • GlobeNewswire

    MYnd Analytics and Emmaus Life Sciences Announce Availability of Definitive Joint Proxy Statement/Prospectus Relating to Merger and Spin-off Transaction

    MISSION VIEJO, Calif. and TORRANCE, Calif., June 12, 2019 -- MYnd Analytics, Inc. (Nasdaq: MYND), a predictive analytics company aimed at improving the delivery of mental.

  • GlobeNewswire

    MYnd Analytics Announces $2.8 Million Registered Direct Offering

    MYnd Analytics, Inc. (MYND), a behavioral health company with tools and technologies aimed at improving the delivery of mental health services through the combination of telemedicine and data analytics, today announced that certain investors have agreed to purchase approximately $2.8 million of the Company’s common stock in a registered direct offering. The Company entered into a securities purchase agreement with the investors pursuant to which the Company agreed to sell 2,776,491 shares of its common stock at a per share price of $1.02. The Company intends to use the net proceeds for general corporate purposes.

  • GlobeNewswire

    Arcadian Telepsychiatry Signs Agreement with Memorial Hospital at Gulfport to Provide Telehealth Services

    MYnd Analytics, Inc. (MYND), a behavioral health company with tools and technologies aimed at improving the delivery of mental health services through the combination of telemedicine and data analytics, today announced that Arcadian Telepsychiatry, a wholly owned subsidiary of MYnd, has signed an agreement with Memorial to provide telebehavioral health services through its provider network beginning in May. Memorial is one of the most comprehensive healthcare systems in the state, licensed for 303 beds, including a state-designated level II trauma center, two outpatient surgery centers, satellite diagnostic and rehabilitation centers and over 95 physician clinics.

  • GlobeNewswire

    MYnd Analytics Provides Business and Merger Updates

    Merger with Emmaus on Track to Close Arcadian and PEER Online® Attracting Broad Support From Providers MISSION VIEJO, Calif., May 13, 2019 -- MYnd Analytics, Inc. (NASDAQ:.

  • GlobeNewswire

    MYnd Analytics Partners with Care Compass Network to Offer Telebehavioral Health Services

    MYnd Analytics, Inc. (MYND), a behavioral health company with tools and technologies aimed at improving the delivery of mental health services through the combination of telemedicine and data analytics, today announced that its wholly owned subsidiary, Arcadian Telepsychiatry Services LLC, has partnered with Care Compass Network (CCN), to offer telepsychiatry and teletherapy services, through Arcadian’s provider network.

  • GlobeNewswire

    MYnd Analytics Interviewed on Bloomberg International on the RedChip Money Report

    MYnd Analytics, Inc. (MYND), a behavioral health company with tools and technologies aimed at improving the delivery of mental health services through the combination of telemedicine and data analytics, today announced an interview with its Chairman of the Board, Robin L. Smith, MD, MBA, aired on The RedChip Money Report television program. In the exclusive interview, Dr. Smith discussed MYnd Analytics recent developments, key industry trends and growth drivers, as well as insight regarding the Company’s acquisition of Emmaus and its FDA-approved sickle cell treatment. MYnd Analytics, Inc. (www.myndanalytics.com), with its wholly owned subsidiary Arcadian Telepsychiatry Services LLC, is a technology-enabled telepsychiatry and teletherapy company that provides enhanced access to behavioral health services, improves patient outcomes and helps lower the costs associated with behavioral health issues.

  • ACCESSWIRE

    MYND ALERT: Monteverde & Associates PC Encourages MYnd Analytics, Inc. Shareholders to Contact the Firm

    NEW YORK, NY / ACCESSWIRE / April 26, 2019 / Juan Monteverde , founder and managing partner at Monteverde & Associates PC , a national securities firm headquartered at the Empire State Building in New ...

  • GlobeNewswire

    MYnd Analytics Interview to Air on Bloomberg International on the RedChip Money Report

    MYnd Analytics, Inc. (MYND), a behavioral health company with tools and technologies aimed at improving the delivery of mental health services through the combination of telemedicine and data analytics, today announced an interview with its Chairman of the Board, Robin L. Smith, MD, MBA, will air on The RedChip Money Report television program. The interview will air Sunday, April 21, on Bloomberg International, available in 149 million homes across Europe, the Middle East, and Africa. In the exclusive interview, Dr. Smith discusses MYnd Analytics’ recent developments, key industry trends and growth drivers, as well as insight regarding the Company’s acquisition of Emmaus and its FDA-approved sickle cell treatment.

  • GlobeNewswire

    MYnd Analytics CEO to Present at the ThinkEquity Conference in New York City

    MYnd Analytics, Inc. (MYND), a behavioral health company with tools and technologies aimed at improving the delivery of mental health services through the combination of telemedicine and data analytics, today announced that Patrick Herguth, Chief Executive Officer, is scheduled to present at the ThinkEquity Conference on Thursday, May 2, at 11:00 AM Eastern Time being held at The Mandarin Oriental Hotel in New York City. MYnd Analytics, Inc. (www.myndanalytics.com), with its wholly owned subsidiary Arcadian Telepsychiatry Services LLC, is a technology-enabled telepsychiatry and teletherapy company that provides enhanced access to behavioral health services, improves patient outcomes and helps lower the costs associated with behavioral health issues.

  • PR Newswire

    Lifshitz & Miller LLP Announces Investigation of AmpliPhi Biosciences Corporation, Churchill Capital Corporation, DaVita Inc., Flex Pharma, Inc., MYnd Analytics, Inc., SunCoke Energy Partners, L.P., Top Image Systems Ltd., and Uniti Financial Corporation

    NEW YORK , April 5, 2019 /PRNewswire/ -- AmpliPhi Biosciences Corporation (APHB) Lifshitz & Miller  announces investigation into possible breach of fiduciary duties in connection with the sale of APHB ...

  • GlobeNewswire

    MYnd Analytics to Host Investor Webinar on April 4 to Provide Update on Recent Developments

    MYnd Analytics, Inc. (MYND), a behavioral health company with tools and technologies aimed at improving the delivery of mental health services through the combination of telemedicine and data analytics, will host an investor webinar and live Q&A session on Thursday, April 4, at 11:00 a.m. EST. The webinar will feature a presentation by CEO Patrick Herguth and Chairman Robin L. Smith, MD, MBA discussing MYnd Analytics’ recent developments, key industry trends and growth drivers, as well as insight regarding the Company’s acquisition of Emmaus and its FDA-approved sickle cell treatment. MYnd Analytics, Inc. (www.myndanalytics.com), with its wholly owned subsidiary Arcadian Telepsychiatry Services LLC, is a technology-enabled telepsychiatry and teletherapy company that provides enhanced access to behavioral health services, improves patient outcomes and helps lower the costs associated with behavioral health issues.

  • GlobeNewswire

    MYnd Analytics Awarded European Patent on Neuromodulation Platform; Predicts Patients Likely to Respond to TMS for Treating Depression

    MYnd Analytics, Inc. (MYND), a behavioral health company with tools and technologies aimed at improving the delivery of mental health services through the combination of telemedicine and data analytics, today announced it has received its first notice of patent allowance in Europe on the Company’s neuromodulation platform for predicting patients likely to respond to Transcranial Magnetic Stimulation (TMS). The allowed patent application is entitled “Method for Assessing the Susceptibility of a Human Individual Suffering from a Psychiatric or Neurological Disorder to Neuromodulation Treatment,” and has an anticipated expiration date in 2029.  The patent has as its subject matter the Company’s proprietary process and proprietary outcome data on the use of individualized Quantitative EEG (QEEG) features to predict non-response of individuals to TMS therapy.

  • GlobeNewswire

    CEO of Arcadian Telepsychiatry Services Invited by URAC to Present at the 2019 Telemed Leadership Forum

    MYnd Analytics, Inc. (MYND), a predictive analytics and telehealth company aimed at improving the delivery of mental health through the combination of telemedicine and data analytics, today announced that its wholly owned subsidiary, Arcadian Telepsychiatry Services LLC, has been invited to present at the 2019 Telemed Leadership Forum, entitled, “Transforming Healthcare Delivery,” in Washington, DC, on April 3-5, 2019.  The Forum is hosted by the Utilization Review Accreditation Commission (URAC).

  • ACCESSWIRE

    These 4 Tech Stocks Are On The Rise On Wednesday (3/13/19)

    CORAL GABLES, FL / ACCESSWIRE / March 13, 2019 / The future of the tech stock market directly related to the ability of companies in the tech industry to combat the growing obstacles facing humanity. In ...

  • GlobeNewswire

    MYnd Analytics Joins Magellan Healthcare Provider Network to Offer Telebehavioral Health Services

    MYnd Analytics, Inc. (MYND), a predictive analytics company aimed at improving the delivery of mental health through the combination of telemedicine and data analytics, today announced that its wholly owned subsidiary, Arcadian Telepsychiatry Services LLC, has joined the Magellan Healthcare behavioral health provider network to offer telepsychiatry, teletherapy and teleEAP services to its members through Arcadian’s provider network.

  • GlobeNewswire

    MYnd Analytics and Arcadian Telepsychiatry Services Announce Partnership with IMPACT Solutions to Provide Tele-EAP Services

    MYnd Analytics, Inc. (MYND), a market leader in improving the delivery of mental health through the combination of telemedicine and data analytics/augmented intelligence, today announced a partnership with IMPACT Solutions, a leading provider of behavior healthcare and Employee Assistance Programs (EAP) with a broad range of clients across the Midwest, as well as nationally. Under the agreement, Arcadian will provide tele-EAP services for IMPACT Solutions’ customers through its provider network.

  • PR Newswire

    SHAREHOLDER ALERT: Monteverde & Associates PC Announces an Investigation of MYnd Analytics, Inc. - MYND

    NEW YORK , Feb. 26, 2019 /PRNewswire/ --  Juan Monteverde , founder and managing partner at Monteverde & Associates PC , a national securities firm headquartered at the Empire State Building in New York ...

  • GlobeNewswire

    MYnd Analytics Provides Business Update

    MYnd Analytics, Inc. (MYND), a predictive analytics company aimed at improving the delivery of mental health through the combination of telemedicine and data analytics, today provided the following business update and letter to shareholders from the Company’s CEO, Patrick Herguth.  The Company also reported it has filed its quarterly report on Form 10-Q for the period ending December 31, 2018, which is available at: www.sec.gov.

  • GlobeNewswire

    U.S. General Services Administration Awards Federal Supply Schedule to MYnd Analytics to Provide Healthcare IT Services to the Federal Government

    MYnd Analytics, Inc. (MYND), a predictive analytics company aimed at improving the delivery of mental health through the combination of telemedicine and data analytics, today announced that the U.S. General Services Administration has awarded a five-year Federal Supply Schedule (FSS) contract as a government supplier, effective January 31, 2019 with the opportunity to renew it for 15 more years. Under the contract, MYnd intends to offer Healthcare Information Technology services to federal government departments and agencies related to our Psychiatric EEG Evaluation Registry, including the Department of Defense and the United States Department of Veterans Affairs (VA) facilities nationwide.

  • GlobeNewswire

    MYnd Analytics and Emmaus Life Sciences Provide Update to Shareholders Addressing Questions Related to Merger and Spin-off Transaction

    What percentage of MYnd (to be renamed “Emmaus Life Sciences, Inc.” and referred to as “New Emmaus”) will current MYnd Analytics (“MYnd”) shareholders own upon completion of the transaction? MYnd shareholders will own 5.9% of the fully diluted shares of Emmaus post closing.

  • GlobeNewswire

    MYnd Analytics and Emmaus Life Sciences Announce Merger and Spin-off Transaction

    Emmaus’ commercial lead product Endari™ (L-glutamine oral powder) is FDA approved to reduce the acute complications of sickle cell disease Endari addresses a $3 billion.